Hedge Funds Eye Next Biopharma IPO

A slew of hedge funds filed plans to sell shares in one of this year’s IPO home runs.


Illustration by II

Several hedge funds are gearing up for another biopharma IPO, hoping it will be as successful as a handful of others this year.

Carmot Therapeutics filed plans on November 17 to go public, according to a regulatory filing. It has not yet indicated the number of shares it plans to sell or the anticipated price range.

To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.